Catalyst Pharmaceutical Partners, Inc. CPRX (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that safety and efficacy results from its Firdapse™ Phase 3 trial will be presented as part of an Industry Forum at the 61st Annual Meeting of the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) being held at the Savannah, Georgia International Trade and Convention Center, Oct. 29-Nov. 1. The Catalyst-sponsored forum will occur on Friday, Oct, 31 at 12:00 pm EDT and include presentations on the diagnosis and treatment of LEMS and Congenital Myasthenic Syndrome (CMS) by several Firdapse Phase 3 clinical study investigators and the Firdapse Expanded Access Program (EAP) by Catalyst's chief medical officer. Catalyst will also be exhibiting at booth #515 during the AANEM. The presentation materials will be posted at www.catalystpharma.com in the Investors section under Events & Presentations.
October 31st Agenda: "New Advances in the Diagnosis and Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS)"
Clinical Features and Pathophysiology of Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndrome (CMS)
Perry Shieh, MD, PhD
Associate Professor
Director, Neuromuscular Program
UCLA Medical Center
Electrodiagnosis and Management of LEMS
Yuen So, MD, PhD
Professor of Neurology
Chief, Neurology Clinic
Stanford University Medical Center
Initial Firdapse™ Pivotal Phase 3 Study Safety Results
Mazen Dimachkie, MD
Professor of Neurology
University of Kansas Medical Center
Initial Firdapse™Pivotal Phase 3 Study Efficacy Results
Shin J. Oh, MD
Distinguished Professor Emeritus
University of Alabama at Birmingham Medical Center
Serving the LEMS Patient - Firdapse™ Expanded Access Program
Charles Gorodetzky, MD, PhD
Chief Medical Officer
Catalyst Pharmaceuticals
Further information can be found at: http://catalystpharma.com/pdf/CPP14006_Invite_RD27R2_WEB.pdf
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in